- Home
- COE vs NVCT Comparison
COE vs NVCT Comparison
Compare COE & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COE
- NVCT
- Stock Information
- Founded
- COE 2011
- NVCT 2020
- Country
- COE Singapore
- NVCT United States
- Employees
- COE 310
- NVCT N/A
- Industry
- COE Other Consumer Services
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- COE Real Estate
- NVCT Health Care
- Exchange
- COE Nasdaq
- NVCT Nasdaq
- Market Cap
- COE 113.7M
- NVCT 170.3M
- IPO Year
- COE 2016
- NVCT 2022
- Fundamental
- Price
- COE $19.88
- NVCT $8.35
- Analyst Decision
- COE
- NVCT Strong Buy
- Analyst Count
- COE 0
- NVCT 1
- Target Price
- COE N/A
- NVCT $11.00
- AVG Volume (30 Days)
- COE 10.3K
- NVCT 92.4K
- Earning Date
- COE 03-21-2025
- NVCT 05-06-2025
- Dividend Yield
- COE N/A
- NVCT N/A
- EPS Growth
- COE N/A
- NVCT N/A
- EPS
- COE N/A
- NVCT N/A
- Revenue
- COE $41,924,000.00
- NVCT N/A
- Revenue This Year
- COE N/A
- NVCT N/A
- Revenue Next Year
- COE N/A
- NVCT N/A
- P/E Ratio
- COE N/A
- NVCT N/A
- Revenue Growth
- COE 69.79
- NVCT N/A
- 52 Week Low
- COE $6.00
- NVCT $4.44
- 52 Week High
- COE $25.70
- NVCT $12.10
- Technical
- Relative Strength Index (RSI)
- COE 52.48
- NVCT 66.50
- Support Level
- COE $18.24
- NVCT $6.00
- Resistance Level
- COE $20.29
- NVCT $7.99
- Average True Range (ATR)
- COE 0.98
- NVCT 0.65
- MACD
- COE 0.13
- NVCT 0.11
- Stochastic Oscillator
- COE 89.28
- NVCT 94.66
About COE 51Talk Online Education Group
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.